{
  "meta": {
    "title": "58_Antiplatelets_Fibrinolytics_And_Antifibrinolytics",
    "url": "https://brainandscalpel.vercel.app/58-antiplatelets-fibrinolytics-and-antifibrinolytics-ec4f5d62.html",
    "scrapedAt": "2025-11-30T12:34:36.885Z"
  },
  "questions": [
    {
      "text": "A patient with a history of myocardial infarction has been on 75 mg aspirin OD for two years. The drug primarily acts by inhibiting which enzyme?",
      "choices": [
        {
          "id": 1,
          "text": "Cyclooxygenase 1"
        },
        {
          "id": 2,
          "text": "Cyclooxygenase 2"
        },
        {
          "id": 3,
          "text": "Both a and b"
        },
        {
          "id": 4,
          "text": "Lipoxygenase"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Aspirin</strong> at <strong>low doses</strong>&nbsp;(75mg) primarily acts by <strong>inhibiting&nbsp;</strong><strong>cyclooxygenase 1 (COX-1).</strong></p>\n<p>Low-dose aspirin, used for antiplatelet action, results in selective inhibition of platelet COX-1 (<strong>thromboxane synthase</strong>) inhibiting its ability to form thromboxane A2 (needed for platelet aggregation).</p>\n<p>As platelets lack nuclei, new platelets have to be formed (life span of <strong>7-10 days</strong>) for the return of COX-1 activity.</p>\n<p>At <strong>higher doses</strong> (~1g/day), aspirin also <strong>inhibits COX-2</strong> and results in decreased production of prostacyclin from endothelium. This may nullify the beneficial anti-aggregatory effect of aspirin.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/86e4d0d5598943c3b1b9608e6621be8dx1279x1740.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8079",
      "difficulty": "medium"
    },
    {
      "text": "A 55-year-old underwent coronary stent implantation. He was prescribed dual antiplatelet therapy for 6 months in which clopidogrel is one of the components. Which of the following is not true about this drug?",
      "choices": [
        {
          "id": 1,
          "text": "It inhibits Gp IIb/IIIa receptors"
        },
        {
          "id": 2,
          "text": "The onset of action is slow"
        },
        {
          "id": 3,
          "text": "It is activated by the hepatic CYP2C19"
        },
        {
          "id": 4,
          "text": "It has a long duration of action"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Clopidogrel</strong> acts by irreversible inhibition of<strong> P2Y<sub>12</sub> receptors</strong> of the platelets.</p>\n<p>Options B and C: The onset of action is <strong>slow</strong>&nbsp;(starts after 4 hours) as it requires <strong>metabolic activation</strong> by the hepatic <strong>CYP2C19</strong> enzyme.&nbsp;Patients with a loss of function mutation of the&nbsp;CYP2C19&nbsp;allele exhibit&nbsp;reduced platelet inhibition&nbsp;and experience a&nbsp;higher rate of cardiovascular events.</p>\n<p>Option D: Due to <strong>irreversible inhibition</strong> of platelet P2Y<sub>12</sub> receptors the duration of action is long and lasts for<strong> 5-7 days</strong>.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d700b764308341ee86adcd820bd63332x1279x1740.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Classification of anti-platelet drugs</h3><table>\n<tbody>\n<tr>\n<td><span><strong>Class</strong></span></td>\n<td><span><strong>Drugs</strong></span></td>\n</tr>\n<tr>\n<td><span>Cyclooxygenase- I inhibitors</span></td>\n<td><span>Aspirin</span></td>\n</tr>\n<tr>\n<td><span>Irreversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td>\n<p><span>Ticlopidine, Clopidogrel, Prasugrel</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Reversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td><span>Ticagrelor, Cangrelor</span></td>\n</tr>\n<tr>\n<td><span>GpIIb/IIIa inhibitors</span></td>\n<td><span>Abciximab, Eptifibatide, Tirofiban</span></td>\n</tr>\n<tr>\n<td><span>Thrombin (PAR-1) receptor antagonist</span></td>\n<td><span>Vorapaxar&nbsp;</span></td>\n</tr>\n<tr>\n<td><span>Phosphodiesterase inhibitors</span></td>\n<td>\n<p class=\"p1\"><span>Dipyridamole</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8080",
      "difficulty": "medium"
    },
    {
      "text": "The efficacy of which of the following antiplatelet drugs will be reduced, if omeprazole is used concurrently?",
      "choices": [
        {
          "id": 1,
          "text": "Clopidogrel"
        },
        {
          "id": 2,
          "text": "Prasugrel"
        },
        {
          "id": 3,
          "text": "Ticagrelor"
        },
        {
          "id": 4,
          "text": "Vorapaxar"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Clopidogrel </strong>is a prodrug that is converted into an&nbsp;active metabolite by the <strong>CYP2C19</strong> <strong>enzyme</strong> and<strong>&nbsp;</strong>omeprazole can reduce the efficacy of clopidogrel due to its <strong>CYP2C19 inhibitory activity.&nbsp;</strong></p>\n<p>Option B: Prasugrel is converted to its active metabolite mainly by <strong>other CYP enzymes</strong> and therefore omeprazole does not interfere in its activation.</p>\n<p>Option C: Ticagrelor does not require activation and is metabolized by the<strong> CYP3A4 enzyme.</strong>&nbsp;</p>\n<p>Option D: Vorapaxar is a thrombin receptor antagonist that is also metabolized by the <strong>CYP3A4 enzyme</strong>.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8083",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not a prodrug?",
      "choices": [
        {
          "id": 1,
          "text": "Clopidogrel"
        },
        {
          "id": 2,
          "text": "Prasugrel"
        },
        {
          "id": 3,
          "text": "Ticagrelor"
        },
        {
          "id": 4,
          "text": "Ticlopidine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Ticagrelor</strong>&nbsp;is <strong>not a prodrug</strong> and does not require metabolic activation to exert its antiplatelet action.</p>\n<p>It is an orally active, <strong>reversible antagonist of P2Y12</strong> subtype of ADP receptors. Since the drug does not require hepatic activation, it can be <strong>used in patients with CYP2C19 mutations.</strong>&nbsp;Ticagrelor is metabolized into another active metabolite&nbsp;by CYP3A4 and is finally excreted in the urine.</p>\n<p>Clopidogrel, prasugrel, and ticlopidine are <strong>irreversible</strong> antagonists of P2Y12 and are <strong>prodrugs</strong> requiring metabolic activation.</p><hr><h3>Related Pearl: Classification of anti-platelet drugs</h3><table>\n<tbody>\n<tr>\n<td><span><strong>Class</strong></span></td>\n<td><span><strong>Drugs</strong></span></td>\n</tr>\n<tr>\n<td><span>Cyclooxygenase- I inhibitors</span></td>\n<td><span>Aspirin</span></td>\n</tr>\n<tr>\n<td><span>Irreversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td>\n<p><span>Ticlopidine, Clopidogrel, Prasugrel</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Reversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td><span>Ticagrelor, Cangrelor</span></td>\n</tr>\n<tr>\n<td><span>GpIIb/IIIa inhibitors</span></td>\n<td><span>Abciximab, Eptifibatide, Tirofiban</span></td>\n</tr>\n<tr>\n<td><span>Thrombin (PAR-1) receptor antagonist</span></td>\n<td><span>Vorapaxar&nbsp;</span></td>\n</tr>\n<tr>\n<td><span>Phosphodiesterase inhibitors</span></td>\n<td>\n<p class=\"p1\"><span>Dipyridamole</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8085",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements is true about prasugrel?",
      "choices": [
        {
          "id": 1,
          "text": "It is a reversible inhibitor of ADP receptor"
        },
        {
          "id": 2,
          "text": "Has a slower onset of action than clopidogrel"
        },
        {
          "id": 3,
          "text": "It is contraindicated in cerebrovascular accidents"
        },
        {
          "id": 4,
          "text": "Dose adjustment is needed in renal impairment"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Prasugrel is <strong>contraindicated</strong> in&nbsp;cerebrovascular accidents as it&nbsp;is associated with higher rates of fatal and life-threatening bleeding.&nbsp;</p>\n<p>Option A: It is an <strong>irreversible</strong> inhibitor of the ADP (P2Y<sub>12</sub>) receptor of platelets.</p>\n<p>Option B: It has a <strong>faster</strong> onset of action and produces&nbsp;greater inhibition of platelets than clopidogrel.&nbsp;</p>\n<p>Option D: <strong>Dose adjustment</strong>&nbsp;is<strong> not needed</strong> in moderate hepatic and renal impairment.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1205",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs does not act by blocking Gp IIb/ IIIa receptors?",
      "choices": [
        {
          "id": 1,
          "text": "Abciximab"
        },
        {
          "id": 2,
          "text": "Eptifibatide"
        },
        {
          "id": 3,
          "text": "Tirofiban"
        },
        {
          "id": 4,
          "text": "Vorapaxar"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p class=\"p1\"><strong>Vorapaxar</strong> is a competitive antagonist of <strong>PAR-1</strong> (thrombin receptor) and inhibits thrombin-induced platelet aggregation.</p>\n<p class=\"p1\">Abciximab, tirofiban, and eptifibatide act by <strong>blocking Gp IIb/IIIa receptors</strong>. They are used in patients undergoing&nbsp;percutaneous coronary intervention (PCI) for acute coronary syndrome. They carry a high risk of bleeding and can cause <strong>thrombocytopenia</strong>.</p>\n<p class=\"p1\"><strong>Eptifibatide</strong> is contraindicated in renal failure and <strong>tirofiban</strong> needs dose adjustment in cases of renal impairment.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8a294fc581a94b0dbb3ebd8b07b09fcax1279x1740.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Classification of anti-platelet drugs</h3><table>\n<tbody>\n<tr>\n<td><span><strong>Class</strong></span></td>\n<td><span><strong>Drugs</strong></span></td>\n</tr>\n<tr>\n<td><span>Cyclooxygenase- I inhibitors</span></td>\n<td><span>Aspirin</span></td>\n</tr>\n<tr>\n<td><span>Irreversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td>\n<p><span>Ticlopidine, Clopidogrel, Prasugrel</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Reversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td><span>Ticagrelor, Cangrelor</span></td>\n</tr>\n<tr>\n<td><span>GpIIb/IIIa inhibitors</span></td>\n<td><span>Abciximab, Eptifibatide, Tirofiban</span></td>\n</tr>\n<tr>\n<td><span>Thrombin (PAR-1) receptor antagonist</span></td>\n<td><span>Vorapaxar&nbsp;</span></td>\n</tr>\n<tr>\n<td><span>Phosphodiesterase inhibitors</span></td>\n<td>\n<p class=\"p1\"><span>Dipyridamole</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8091",
      "difficulty": "easy"
    },
    {
      "text": "A patient with a urine output of 0.4ml/Kg per hour in the last 6 hours can be safely administered which of the following GP IIb/IIIa antagonists?",
      "choices": [
        {
          "id": 1,
          "text": "Abciximab"
        },
        {
          "id": 2,
          "text": "Eptifibatide"
        },
        {
          "id": 3,
          "text": "Tirofiban"
        },
        {
          "id": 4,
          "text": "All of the above"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Abciximab</strong>&nbsp;can safely be administered to this patient who is likely suffering from <strong>acute kidney injury</strong> (urine volume less than 0.5 mL/kg per hour for 6 hours).&nbsp; &nbsp;</p>\n<p>Abciximab, eptifibatide, and tirofiban are parenteral <strong>GpIIb/IIIa receptor antagonists</strong> used in the treatment of acute coronary syndromes.</p>\n<p class=\"p1\"><strong>Eptifibatide</strong> is <strong>contraindicated</strong> in renal failure and <strong>tirofiban</strong> needs <strong>dose adjustment</strong> in cases of renal impairment. Both these drugs undergo renal clearance and used cautiously in renal impairment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1206",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old male patient requires percutaneous coronary intervention. He was given an IV infusion of a reversible ADP receptor inhibitor. Which of the following drugs was used?",
      "choices": [
        {
          "id": 1,
          "text": "Abciximab"
        },
        {
          "id": 2,
          "text": "Eptifibatide"
        },
        {
          "id": 3,
          "text": "Cangrelor"
        },
        {
          "id": 4,
          "text": "Tirofiban"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Cangrelor</strong> is a <strong>parenteral</strong>, reversible ADP receptor (<strong>P2Y<sub>12</sub></strong> <strong>receptor</strong>) inhibitor, administered intravenously.</p>\n<p>Abciximab, eptifibatide, and tirofiban are parenteral agents too but, they are <strong>GPIIb/IIIa</strong> <strong>inhibitors</strong>.</p><hr><h3>Related Pearl: Classification of anti-platelet drugs</h3><table>\n<tbody>\n<tr>\n<td><span><strong>Class</strong></span></td>\n<td><span><strong>Drugs</strong></span></td>\n</tr>\n<tr>\n<td><span>Cyclooxygenase- I inhibitors</span></td>\n<td><span>Aspirin</span></td>\n</tr>\n<tr>\n<td><span>Irreversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td>\n<p><span>Ticlopidine, Clopidogrel, Prasugrel</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Reversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td><span>Ticagrelor, Cangrelor</span></td>\n</tr>\n<tr>\n<td><span>GpIIb/IIIa inhibitors</span></td>\n<td><span>Abciximab, Eptifibatide, Tirofiban</span></td>\n</tr>\n<tr>\n<td><span>Thrombin (PAR-1) receptor antagonist</span></td>\n<td><span>Vorapaxar&nbsp;</span></td>\n</tr>\n<tr>\n<td><span>Phosphodiesterase inhibitors</span></td>\n<td>\n<p class=\"p1\"><span>Dipyridamole</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3186",
      "difficulty": "easy"
    },
    {
      "text": "After suffering from a myocardial infarction, a patient was started on two drugs X and Y. The drug X inhibits the COX-1 enzyme and drug Y inhibits thrombin-induced platelet aggregation. Identify the drugs.",
      "choices": [
        {
          "id": 1,
          "text": "X- Aspirin, Y- Clopidogrel"
        },
        {
          "id": 2,
          "text": "X- Clopidogrel, Y- Vorapaxar"
        },
        {
          "id": 3,
          "text": "X- Aspirin, Y- Vorapaxar"
        },
        {
          "id": 4,
          "text": "X- Aspirin, Y- Cangrelor"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>X- Aspirin</strong> and <strong>Y- Vorapaxar</strong> are the drugs<strong>&nbsp;</strong>administered to the patient.</p>\n<p><strong>Aspirin</strong> reduces thromboxane A2 production by inhibiting the <strong>COX-1 enzyme.</strong>&nbsp;</p>\n<p><strong>Vorapaxar</strong> is a <strong>competitive antagonist of PAR-1</strong> and inhibits thrombin-induced platelet aggregation. Vorapaxar is indicated in combination with aspirin and/or clopidogrel to reduce thromboembolic events in patients with MI or peripheral vascular disease.</p><hr><h3>Related Pearl: Classification of anti-platelet drugs</h3><table>\n<tbody>\n<tr>\n<td><span><strong>Class</strong></span></td>\n<td><span><strong>Drugs</strong></span></td>\n</tr>\n<tr>\n<td><span>Cyclooxygenase- I inhibitors</span></td>\n<td><span>Aspirin</span></td>\n</tr>\n<tr>\n<td><span>Irreversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td>\n<p><span>Ticlopidine, Clopidogrel, Prasugrel</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Reversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td><span>Ticagrelor, Cangrelor</span></td>\n</tr>\n<tr>\n<td><span>GpIIb/IIIa inhibitors</span></td>\n<td><span>Abciximab, Eptifibatide, Tirofiban</span></td>\n</tr>\n<tr>\n<td><span>Thrombin (PAR-1) receptor antagonist</span></td>\n<td><span>Vorapaxar&nbsp;</span></td>\n</tr>\n<tr>\n<td><span>Phosphodiesterase inhibitors</span></td>\n<td>\n<p class=\"p1\"><span>Dipyridamole</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3184",
      "difficulty": "medium"
    },
    {
      "text": "How is alteplase differentiated from streptokinase?",
      "choices": [
        {
          "id": 1,
          "text": "It is longer acting"
        },
        {
          "id": 2,
          "text": "It is cheap"
        },
        {
          "id": 3,
          "text": "It is derived from human kidney"
        },
        {
          "id": 4,
          "text": "It has more affinity towards plasminogen bound to fibrin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Alteplase</strong> differs from streptokinase as it has <strong>more affinity </strong>towards plasminogen bound to fibrin.</p>\n<p>It activates fibrin-bound plasminogen <strong>more rapidly</strong> than it activates plasminogen in the circulation. Streptokinase activates both free and fibrin bound plasminogen.&nbsp;</p>\n<p>Option A: Alteplase is <strong>rapidly cleared</strong> by the liver and inactivated by plasminogen activator inhibitor-1 making it <strong>shorter-acting</strong> than streptokinase.</p>\n<p>Option B: It is also more expensive than streptokinase&nbsp;</p>\n<p>Option C: Alteplase is the <strong>recombinant </strong>tissue-type plasminogen activator derived from <strong>human tissue (endothelial cells) culture.</strong></p><hr><h3>Related Pearl: Plasminogen activators (classification of fibrinolytics)</h3><p><strong>Fibrin non-specific</strong> plasminogen activators</p>\n<ul>\n<li>Streptokinase - least fibrin specific and has the lowest incidence of intracranial hemorrhage</li>\n<li>Anistreplase</li>\n<li>Urokinase</li>\n</ul>\n<p><strong>Fibrin specific</strong> plasminogen activators</p>\n<ul>\n<li>Alteplase - has the shortest half-life</li>\n<li>Tenecteplase - most fibrin specific and given as a single bolus dose</li>\n<li>Reteplase</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8104",
      "difficulty": "medium"
    },
    {
      "text": "In patients with which of the following conditions would fibrinolytic therapy be an absolute contraindication?<div class='question-desc-html'><ol>\n<li>Active peptic ulcer</li>\n<li>Ischaemic stroke in past 3 months</li>\n<li>Menstrual bleeding&nbsp;</li>\n<li>Suspected aortic dissection</li>\n<li>Uncontrolled hypertension</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 3 and 5"
        },
        {
          "id": 2,
          "text": "2 and 4"
        },
        {
          "id": 3,
          "text": "3 and 4"
        },
        {
          "id": 4,
          "text": "1 and 2"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Among the given options, <strong>ischaemic stroke in the past 3 months</strong> and <strong>suspected aortic dissection</strong>&nbsp;are <strong>absolute</strong> contraindications to fibrinolytic therapy.</p>\n<p>Active peptic ulcer and uncontrolled hypertension are <strong>relative</strong> contraindications for fibrinolytic therapy. Menstruation is <strong>not</strong> a contraindication to fibrinolytic therapy.&nbsp;</p>\n<p>Note: History of a&nbsp;<strong>hemorrhagic stroke</strong> at any time is an <strong>absolute contraindication</strong> for thrombolytic therapy.</p><hr><h3>Related Pearl: Contraindications for thrombolytic therapy</h3><p>The <strong>absolute contraindications</strong> for thrombolytic therapy are:</p>\n<ul>\n<li>Prior intracranial hemorrhage</li>\n<li>Known structural cerebral vascular lesion</li>\n<li>Known malignant intracranial neoplasm</li>\n<li>Ischemic stroke within 3 months</li>\n<li>Suspected aortic dissection</li>\n<li>Active bleeding or bleeding diathesis (excluding menses)</li>\n<li>Significant closed head trauma or facial trauma within 3 months</li>\n</ul>\n<p>The <strong>relative contraindications</strong> for thrombolytic therapy are:</p>\n<ul>\n<li>Uncontrolled hypertension (SBP&gt;180 mm Hg; DBP&gt;110 mmHg)</li>\n<li>Traumatic or prolonged CPR or major surgery within 3 weeks</li>\n<li>Recent (2-4 weeks) internal bleeding</li>\n<li>Noncompressible vascular punctures</li>\n<li>Pregnancy</li>\n<li>Active peptic ulcer</li>\n<li>Current use of warfarin and INR&gt;1.7</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8101",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a recombinant tissue-type plasminogen activator?",
      "choices": [
        {
          "id": 1,
          "text": "Alteplase"
        },
        {
          "id": 2,
          "text": "Anistreplase"
        },
        {
          "id": 3,
          "text": "Tenecteplase"
        },
        {
          "id": 4,
          "text": "Reteplase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Anistreplase</strong> is <strong>not</strong> a recombinant tissue plasminogen activator (rtPA).</p>\n<p>Anistreplase (anisoylated plasminogen streptokinase activator complex) is a&nbsp;<strong>preformed complex</strong> of human&nbsp;<strong>plasminogen</strong> and bacterial&nbsp;<strong>streptokinase </strong>which is used as a thrombolytic agent.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8103",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following plasminogen activator can be administered as a single bolus dose for a patient who requires coronary thrombolysis?",
      "choices": [
        {
          "id": 1,
          "text": "Alteplase"
        },
        {
          "id": 2,
          "text": "Tenecteplase"
        },
        {
          "id": 3,
          "text": "Reteplase"
        },
        {
          "id": 4,
          "text": "Anistreplase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Tenecteplase</strong> can be administered as a <strong>single bolus</strong> dose for patients requiring coronary thrombolysis.</p>\n<p>Options A and D: Alteplase and anistreplase are administered as&nbsp;<strong>intravenous infusion.</strong></p>\n<p>Option C: Reteplase can also be given as <strong>two IV boluses</strong>, given 30 minutes apart.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8106",
      "difficulty": "medium"
    },
    {
      "text": "A 35-year-old woman came to the gynecology OPD with a history of heavy menstrual bleeding. She complained of having to change 4-5 pads in a day and an increase in bleeding to more than 7 days since the last few months. Which of the following is the preferred drug that can be given to this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Mefenamic acid"
        },
        {
          "id": 2,
          "text": "Tranexamic acid"
        },
        {
          "id": 3,
          "text": "Epsilon amino caproic acid"
        },
        {
          "id": 4,
          "text": "Acetylsalicylic acid"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Tranexamic acid</strong> is the drug approved for treating&nbsp;<strong>heavy menstrual bleeding</strong>.&nbsp;&nbsp;</p>\n<p>It is a lysine analogue&nbsp;that binds to the active site of plasmin and prevents the interaction of fibrin with plasmin. This prevents the dissolution of clots and decreases bleeding.</p>\n<p>Option A: <strong>Mefenamic acid</strong> is an NSAID and indicated in primary <strong>dysmenorrhea</strong>.</p>\n<p class=\"p1\">Option C: <strong>&epsilon;-Aminocaproic acid</strong> is also an <strong>antifibrinolytic agent</strong> like tranexamic acid. However, it is not approved for heavy menstrual bleeding.</p>\n<p>Option D: <strong>Acetylsalicylic acid</strong> is aspirin, an anti-platelet drug.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8112",
      "difficulty": "easy"
    },
    {
      "text": "A 55-year-old man admitted with ischemic stroke was given IV alteplase. After 8 hours, the ICU staff noticed decreasing mental status and acute hypertension in the patient. A repeat CT revealed the following, Which of the following drugs can be used to manage this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Protamine"
        },
        {
          "id": 2,
          "text": "Streptokinase"
        },
        {
          "id": 3,
          "text": "Heparin"
        },
        {
          "id": 4,
          "text": "ε-Aminocaproic acid"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario is suggestive of <strong>post-thrombolytic hemorrhagic transformation</strong> of an ischemic stroke. <strong>ε-Aminocaproic acid</strong> can be used as an antidote for fibrinolytic therapy.</p>\n<p>It is a lysine analog that binds competitively to plasminogen, blocking plasminogen from binding to fibrin and the subsequent conversion to plasmin. This activity subsequently results in the <strong>inhibition of fibrinolysis.</strong></p>\n<p>It should not be given unless hemorrhage is life-threatening because it inhibits intrinsic fibrinolytic activity and <strong>can precipitate DIC.</strong> Fresh frozen plasma and cryoprecipitate may also be used to replenish fibrin and clotting factors.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c5434f9f9b644b03994bd2a670bccd16x1280x1847.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/cb08e9bb3c00434293e681b7169a94d4.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF0589",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is true about prasugrel?",
      "choices": [
        {
          "id": 1,
          "text": "It acts as an P2 Y12 agonist"
        },
        {
          "id": 2,
          "text": "It is 10 times less potent than clopidogrel"
        },
        {
          "id": 3,
          "text": "It is a pro drug"
        },
        {
          "id": 4,
          "text": "Omeprazole interferes in its activation to an active metabolite"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Prasugrel is a <strong>prodrug</strong>.</p>\n<p>It acts as an <strong>irreversible ADP (P<sub>2 </sub>Y<sub>12</sub>) antagonist </strong>and is converted into its active metabolite by <strong>CYP3A4 and CYP2B6</strong>. Since omeprazole is an inhibitor of CYP2C19, it does not interfere with its activation.</p>\n<p>It is 10-times<strong> more potent </strong>than clopidogrel and has a more rapid onset of action because of better absorption and more predictable metabolic activation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7414",
      "difficulty": "medium"
    }
  ]
}